Skip to main content

Avance Clinical Featured in Fierce Biotech on Intranasal Expertise

By October 23, 2021November 2nd, 2021Company News

With the global intranasal drug delivery market estimated to reach up to $71 billion over the next five years, Avance Clinical is seeing an increase in biotech clinical trials targeting this growing market demand. North America is predicted to be the largest market, with China and India the fastest growing in APAC.  

Avance Clinical CEO Yvonne Lungershausen said the demand for intranasal delivery is seen across all therapeutic areas for new chemical entities as well as repurposing of currently approved medications.

“The COVID-19 era has made mucosal immunity a driver for a new generation of intranasal vaccines. Intranasal administration is becoming a preferred delivery route driven by the rise in home healthcare, self-administration, and increasing demand in the aged and pediatric care,” Lungershausen said. READ MORE HERE

Leave a Reply


DOWNLOAD OUR LATEST WHITEPAPER

Why 65% of US Biotechs Struggle to Identify Suitable CRO Partner

By filling in this form you consent to Avance Clinical contacting you. Read our Privacy Policy
This field is for validation purposes and should be left unchanged.

This will close in 0 seconds